XLO PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d ⚠ clustered

XLO ▼ -3.55% at T+20d

NEUTRAL call ✗ call lost -3.55% · α vs SPY -7.75% · entry $8.45 → $8.15

Next anchor: T+60d in 5w

Currently $7.90 · -6.51% from $8.45 entry

Entry anchored
Apr 17, 03:59 PM ET
via Databento tick

T+1d

+0.83%

call +0.83% · α +1.48%

$8.52

settled 7w ago

T+5d

-3.20%

call -3.20% · α -4.11%

$8.18

settled 7w ago

T+20d

-3.55%

call -3.55% · α -7.75%

$8.15

settled 26d ago

T+60d

—

call — · α —

—

in 5w

Price Chart

Loading chart...

Executive Summary

Xilio Therapeutics released preclinical data for XTX601, a masked T cell engager targeting CLDN18.2, demonstrating tumor-selective activation, potent anti-tumor activity, and favorable tolerability in non-human primates. The data support advancement into IND-enabling studies with an IND submission planned for 2027. While promising, these are early-stage results with no clinical efficacy yet demonstrated.

Actionable Insight

Monitor for IND submission in 2027 and any future clinical trial initiation; near-term upside is limited to sentiment shifts from preclinical enthusiasm, but high biotech risk remains due to early stage and lack of human data.

Key Facts

XTX601 is a first-in-class masked T cell engager targeting CLDN18.2, expressed in gastric, pancreatic, and esophageal cancers.
Preclinical data show protease-dependent activation, robust anti-tumor activity in xenograft models, and no cytokine release syndrome or liver enzyme changes in non-human primates.
Xilio plans to submit an IND for XTX601 in 2027, meaning clinical trials are still over a year away.
No human data or financial metrics (revenue, EPS) are available; results are preclinical only.

Financial Impact

No immediate financial impact; potential long-term value if clinical development succeeds

pipeline valueR&D trajectoryinvestor sentiment

Risk Factors

Preclinical results may not translate to humans
Development timelines could be delayed
High dilution risk as company will likely need to raise capital before clinical stages

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3276473

9 reports for XLO

T+1T+5T+20T+60

100% Hit rate 3 of 3 directional calls best @ T+20▲ +8.40%Mar 23, 2026

Filters

Reports for XLO — sortable, filterable
	Type				Now
Jun 1, 2026 8d ago	EFFECT BEARISH ★ 5/10	$8.25 $7.70	▲ +6.67%	▲ +3.92%	$7.90 (+4.24%)
May 27, 2026 13d ago	S-3/A NEUTRAL ★ 4/10	$8.52 $8.15	▼ −4.40%	▼ −4.35%	$7.90 (−7.28%)
May 12, 2026 28d ago	8-K NEUTRAL ★ 4/10	$7.73 $8.15	▲ +5.43%	▲ +5.36%	$7.90 (+2.20%)
May 12, 2026 28d ago	Press Release BULLISH ★ 7/10	$7.73 $8.15	▲ +5.43%	▲ +5.36%	$7.90 (+2.20%)
Apr 17, 2026 7w ago	Press Release MIXED ★ 5/10	$8.45 $8.18	▼ −3.20%	▼ −4.11%	$7.90 (−6.51%)
Apr 16, 2026 7w ago	3 NEUTRAL ★ 2/10	$8.57 $8.31	▼ −3.03%	▼ −3.59%	$7.90 (−7.82%)
Apr 16, 2026 7w ago	8-K NEUTRAL ★ 3/10	$8.35 $8.47	▲ +1.44%	▲ +0.45%	$7.90 (−5.39%)
Mar 23, 2026 11w ago	Press Release BULLISH ★ 8/10	$7.86 $8.24	▲ +4.77%	▲ +8.34%	$7.90 (+0.51%)
Mar 17, 2026 12w ago	Press Release NEUTRAL ★ 4/10	$7.60 $8.53	▲ +12.24%	▲ +12.95%	$7.90 (+3.95%)

US Market Status

Market Closed — Opens Thu (11h 13m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access